Matinas BioPharma Holdings, Inc. (MTNB)
| Market Cap | 140.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.44M |
| Shares Out | 216.87M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153,948 |
| Open | 0.640 |
| Previous Close | 0.636 |
| Day's Range | 0.630 - 0.670 |
| 52-Week Range | 0.490 - 1.260 |
| Beta | 2.00 |
| Analysts | Buy |
| Price Target | 2.81 (+335.1%) |
| Earnings Date | Nov 7, 2022 |
About MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular ... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for MTNB stock is "Buy." The 12-month stock price forecast is 2.81, which is an increase of 335.05% from the latest price.
News
Matinas BioPharma Announces Chairman Succession Plan
Eric J. Ende, MD, MBA Appointed as Chairman, Effective October 1, 2022; Founding Chairman Herbert J. Conrad to Remain an Independent Director of the Company Eric J. Ende, MD, MBA Appointed as Chairman, ...
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)
Matinas Biopharma Holdings, Inc. (MTNB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raisi...
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022
Matinas BioPharma to Participate in the BTIG Biotechnology Conference
BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and s...
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on Augu...
BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucl...
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 ...
BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and s...
Matinas BioPharma to Present at the LD Micro Invitational XII Conference
BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and sm...
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
– Announced an exclusive research collaboration with BioNTech focused on the combination of mRNA and Matinas' proprietary LNC platform technology –
Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial and Operational Results on May 1...
BEDMINSTER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucl...
Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
BEDMINSTER, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and s...
Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech
BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC ...
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mR...
MAINZ, Germany and BEDMINSTER, New Jersey (USA), April 11, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Matinas BioPharma (NYSE AMER: MTNB, “Matinas”), a clinical-stage biopharmaceutical company f...
Matinas BioPharma to Present at the Needham Virtual Healthcare Conference
BEDMINSTER, N.J., April 06, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and...
Matinas BioPharma to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
BEDMINSTER, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and...
Matinas Biopharma Holdings, Inc. (MTNB) Loses 29.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Matinas Biopharma Holdings, Inc. (MTNB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street...
Matinas BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
– Fifteen Patients Enrolled to Date in Cohort 4 of EnACT (all oral induction regimen); Topline Interim Data Expected Q3 2022 –
Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial –
Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022
Conference call and live audio webcast scheduled for Tuesday, January 25th at 8:30 a.m. ET Conference call and live audio webcast scheduled for Tuesday, January 25th at 8:30 a.m. ET
Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT...
– DSMB evaluated both safety and efficacy data in recommending cohort progression –
Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...
Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference
BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of crit...
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead f...
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recomm...